Literature DB >> 20199636

Iodopovidone is as effective as doxycycline in producing pleurodesis in rabbits.

Yubiao Guo1, Kejing Tang, Semra Bilaceroglu, Ioannis Kalomenidis, Kenneth J Salleng, Kirk B Lane, Richard W Light.   

Abstract

BACKGROUND AND
OBJECTIVE: The mechanism by which iodopovidone achieves pleurodesis is unknown. This study investigated whether iodopovidone is as effective as doxycycline in producing pleurodesis and whether systemic corticosteroids diminish its efficacy.
METHODS: Four groups of seven New Zealand rabbits were assigned to the following intrapleural treatment groups: 2 mL of 2% iodopovidone, 2 mL of 4% iodopovidone, 2 mL of 4% iodopovidone plus 0.8 mg/kg triamcinolone intramuscularly weekly and 10 mL/kg doxycycline in 2 mL. Pleural fluid was collected 24, 48 and 72 h after intrapleural injections and analysed for WCC, protein and LDH levels. The rabbits were killed 2 weeks after the injections. Pleurodesis was graded macroscopically on a scale from 1 to 8. The degree of microscopic pleural fibrosis and pleural inflammation was graded from the HE stain slides.
RESULTS: The mean volume of pleural fluid as well as the mean total WCC was significantly lower in the steroid-treated group than in the other groups. The degree of the resulting pleurodesis was similar in the 2% iodopovidone (7.00 +/- 1.29), 4% iodopovidone (7.71 +/- 0.76) and doxycycline (7.14 +/- 0.90) groups (P > 0.05) whereas the pleurodesis score of the steroid group (3.71 +/- 1.98) was significantly lower than all other groups (P < 0.05). The degree of microscopic pleural fibrosis and pleural inflammation was significantly lower in the steroid group than in the 2% iodopovidone or 4% iodopovidone group.
CONCLUSIONS: Both 2% and 4% iodopovidone can induce pleurodesis as efficaciously as doxycycline in rabbits. Systemic corticosteroids significantly decrease the efficacy of iodopovidone in producing pleurodesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20199636     DOI: 10.1111/j.1440-1843.2009.01671.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  7 in total

1.  Iodopovidone pleurodesis for malignant pleural effusions: an updated systematic review and meta-analysis.

Authors:  Valliappan Muthu; Sahajal Dhooria; Inderpaul Singh Sehgal; Kuruswamy Thurai Prasad; Ashutosh N Aggarwal; Ritesh Agarwal
Journal:  Support Care Cancer       Date:  2021-01-30       Impact factor: 3.603

2.  Impact of Factors Secreted by Tumor Cells on Response of Pleural Mesothelial Cells to Different Sclerosing Agents in an In Vitro Model.

Authors:  Michał Mierzejewski; Magdalena Paplińska-Goryca; Rafał Krenke
Journal:  Med Sci Monit       Date:  2022-05-10

3.  Comparison of additional minocycline versus iodopovidone pleurodesis during video-assisted thoracoscopic bleb resection for primary spontaneous pneumothorax: a propensity score-matched analysis.

Authors:  Kang Hoon Lee; Bo Taek Kim; Hyun Koo Kim; Kook Nam Han; Young Ho Choi
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 4.  Chemical pleurodesis - a review of mechanisms involved in pleural space obliteration.

Authors:  Michal Mierzejewski; Piotr Korczynski; Rafal Krenke; Julius P Janssen
Journal:  Respir Res       Date:  2019-11-07

5.  Pleurodesis with povidone iodine in patients with malignant pleural effusion in a tertiary center in Nigeria.

Authors:  Benjamin Irene Omoregbee; Stanley Okugbo
Journal:  Pan Afr Med J       Date:  2021-02-15

6.  HDAC Inhibitor Abrogates LTA-Induced PAI-1 Expression in Pleural Mesothelial Cells and Attenuates Experimental Pleural Fibrosis.

Authors:  Wei-Lin Chen; Mei-Chuan Chen; Shang-Fu Hsu; Shih-Hsin Hsiao; Chi-Li Chung
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

7.  Effectiveness and safety of iodopovidone in an experimental pleurodesis model.

Authors:  Lisete R Teixeira; Francisco S Vargas; Juliana Puka; Milena M P Acencio; Leila Antonangelo; Ricardo M Terra; Francisco M Damico; Fabio G Pitta; Evaldo Marchi
Journal:  Clinics (Sao Paulo)       Date:  2013-04       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.